Mogroside V

Research use only, not for human use.

Mogroside V is a widely used sweetener, has in vitro AMPK activating effect, it also has anti-inflammatory potential in murine macrophages and a murine ear edema model, and has the potential to protect against LPS-induced airway inflammation in a model of ALI.

Mogroside V is a widely used sweetener, has in vitro AMPK activating effect, it also has anti-inflammatory potential in murine macrophages and a murine ear edema model, and has the potential to protect against LPS-induced airway inflammation in a model of ALI. Mogroside V has antioxidant properties and possesses tumor growth inhibitory activity in pancreatic cancer models.

Immunofluorescence Cell Line:IVM oocytes Concentration:20 μM Incubation Time:40 h Result:Increased the fluorescence intensity compared to control group.Increased the red/green fluorescence intensity ratio compared to control group.Real Time qPCR Cell Line:IVM oocytesConcentration:20 μM Incubation Time:40 h Result:Increased the relative mRNA expression of SOD, CAT, PGC-1α and TFAM than in control group.Cell Viability Assay Cell Line:PANC-1 cells Concentration:1-250 μM Incubation Time:24 h Result:Increased the percentage of TUNEL-positive cells ranging from 2.91% to 92.25%.Apoptosis Analysis Cell Line:PANC-1 cellsConcentration:1-250 μM Incubation Time:24 h Result:Induced apoptosis in PANC-1 cells in a concentration- and time-dependent mannerWestern Blot Analysis Cell Line:PANC-1 cells Concentration:0-250 μM Incubation Time:24 h Result:Increased the expression of the cyclin kinase inhibitors CDKN1A (p21WAF1) and CDKN1B (p27) in a dose-dependent manner. Decreased the the expression of the pro-proliferative cell cycle regulators CCND1 (cyclin D1), CCNE1 (cyclin E1) and CDK2.Suppressed phosphorylation of the kinases upstream of STAT3, including that of JAK2 and TYK2.

Animal Model:T2D model ratsDosage:100 mg/kg Administration:Oral gavage (p.o.)Result:Detected 28 metabolites of mogroside V compared to the blank biological samples.Displayed larger peak areas of metabolites in T2D rat plasma samples than those in healthy sample.

——

Membrane Transporter/Ion Channel

TRP/TRPV Channel

AMPK

Others-Field

——

88901-36-4

1287.43

C60H102O29

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (77.67 mM)

[C@@H]12[C@]([C@H]3C(=CC2)C([C@H](CC3)O[C@@H]2O[C@H](CO[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)[C@H]([C@@H]([C@H]2O)O)O)(C)C)([C@@H](C[C@]2([C@]1(CC[C@@H]2[C@@H](CC[C@@H](O[C@H]1[C@H](O[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CO)[C@H]([C@@H]([C@H](O1)CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO)O)O)C(C)(C)O)C)C)C)O)C

——

(-20℃)

With Ice Pack

≥ 2 years